Bezafibrate for severe refractory intrahepatic cholestasis of pregnancy

Bezafibrate is emerging as a promising treatment option for severe refractory intrahepatic cholestasis of pregnancy (ICP), particularly in cases where conventional therapies like ursodeoxycholic acid (UDCA) fail to provide adequate symptom relief or biochemical improvement.

Mechanism of Action:

Bezafibrate works by activating peroxisome proliferator-activated receptor alpha (PPAR-α), a nuclear receptor involved in lipid and bile acid metabolism. Through PPAR-α activation, bezafibrate promotes:

1. Reduction in bile acid synthesis: It decreases the production of bile acids by downregulating cholesterol 7-alpha-hydroxylase (CYP7A1), the enzyme responsible for bile acid synthesis.

2. Enhancement of bile flow: Bezafibrate facilitates bile acid secretion and clearance, reducing the accumulation of toxic bile acids in the liver and bloodstream.

3. Anti-inflammatory effects: PPAR-α activation has anti-inflammatory properties, which may help mitigate liver inflammation and damage associated with ICP.

4. Improvement in pruritus: By reducing bile acid levels, bezafibrate alleviates the hallmark symptom of ICP—severe itching.

Bezafibrate has been successfully used in other cholestatic liver diseases, such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), which further supports its anticholestatic effects.

Safety Profile in Pregnancy:

While data on the use of bezafibrate during pregnancy are limited, emerging evidence suggests that its short-term use may be safe for both the mother and fetus. Key findings regarding its safety profile include:

1. No significant increase in congenital malformations: Recent cohort studies have not identified a higher risk of birth defects associated with fibrate exposure during pregnancy.

2. No adverse neonatal outcomes: Available data indicate that neonates exposed to bezafibrate in utero do not experience significant complications, aside from transient conditions like mild jaundice, which are manageable.

3. Limited long-term safety data: While short-term outcomes appear favorable, long-term effects on fetal development remain under investigation and require further study.

Considerations for Use:

• Bezafibrate may be particularly beneficial in cases of severe ICP where bile acid levels exceed 300 µmol/L and are unresponsive to UDCA.
• Close monitoring of maternal liver function and fetal well-being is essential to ensure safety during bezafibrate therapy.
• Multicenter trials and registries are needed to establish optimal dosing, timing, and long-term safety of bezafibrate during pregnancy.

Conclusion:

Bezafibrate demonstrates significant therapeutic potential for managing severe, treatment-refractory ICP by effectively reducing bile acid levels and alleviating symptoms. While preliminary safety data are reassuring, further research is needed to confirm its safety and efficacy in pregnancy on a larger scale.